PhD Scientific Days

Poster Presentation: Clinical Sciences

P28: Cisplatin induced hearing loss: setting up an animal model

Előadó neve

Talpai, Szabolcs

Előadó munkahelye

Semmelweis University, Dept. of Otorhinolaryngology, Head and Neck Surgery

Előadó telefonszáma

+3620/666 3000

Előadó e-mail címe

szabolcs.talpai.md@gmail.com

Az előadás címe

Cisplatin induced hearing loss: setting up an animal model

Szerző(k) neve és munkahelye

Szabolcs Talpai 1 , Viktória Humli 2,3 , Judit Szepesy 3,1 , László Tamás 1 , Tibor Zelles 2,3 , Anita
Gáborján 1
1 Semmelweis University, Dept. of Otorhinolaryngology, Head and Neck Surgery
2 Institute of Experimental Medicine, Hungarian Academy of Sciences
3 Semmelweis University, Dept. of Pharmacology and Pharmacotherapy

Szekció

Poster Presentation: Clinical Sciences

Data of the presenter

Doctoral School: Clinical Medicine
Program: Otorhinolaryngology, Head and Neck Surgery
Supervisor: Anita Gáborján
E-mail address: szabolcs.talpai.md@gmail.com

Text of the abstract

Cisplatin is a widely used chemotherapeutic agent. Its main indications are malignancies of the head and neck region, testicular cancer and non small cell lung carcinoma. Cisplatin has a number of side effects including nephrotoxicity, nausea, vomiting, neurotoxicity and ototoxicity. In our study we focus on the ototoxicity of the substance.

Our objective was to set up a mouse model for examining the ototoxicity of the substance and try out possible otoprotective agents preventing cisplatin induced hearing loss.

For our measurements we used Auditory Brainstem Response (ABR) which is an objective test for the evaluation of hearing. We have tested different strains of mice such as CD1, NMRI and BALB/c in different ages ranging from 5-12 weeks old animals. Cisplatin was given to the animals in a protocol that the drug was administered for 5 consecutive days, then 2 days rest and 5 more days of treatment again. We used dosages of 2.5 mg/kg, 3.5 mg/kg and 4.5 mg/kg. The weight and temperature of the animals were taken regularly.

CD1 and NMRI strains were excluded from our study since their starting hearing was impaired. We chose BALB/c mice to work with because of their intact hearing. At first we used 5 to 6 weeks old animals, but their general health conditions were not satisfying throughout the treatment, thus we started working with older animals (10-12 weeks old) in later measurements. To validate our preliminary result, repeated rounds were examined of the 2.5 mg/kg and 3.5 mg/kg protocols with 12 weeks old mice. Our results are not final and the study is still running. After the cisplatin induced hearing loss animal model is set we are planning on testing otoprotective compounds on it, making the use of cisplatin safer.

Azonosító

P28

Kind

Szabad

Előadás fájl jóváhagyás

nem rendelkezett róla

Előadó

1255

PhD Scientific Days 2017

Budapest, 11-12 April 2017